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Abstract
Background: Little is known about the role of glial host cells in brain tumours. However, supporting stromal cells
have been shown to foster tumour growth in other cancers.
Methods: We isolated stromal cells from patient-derived glioblastoma (GBM) xenografts established in GFP-NOD/scid
mice. With simultaneous removal of CD11b+ immune and CD31+ endothelial cells by fluorescence activated cell sorting
(FACS), we obtained a population of tumour-associated glial cells, TAGs, expressing markers of terminally differentiaed
glial cell types or glial progenitors. This cell population was subsequently characterised using gene expression analyses
and immunocytochemistry. Furthermore, sphere formation was assessed in vitro and their glioma growth-promoting
ability was examined in vivo. Finally, the expression of TAG related markers was validated in human GBMs.
Results: TAGs were highly enriched for the expression of glial cell proteins including GFAP and myelin basic protein
(MBP), and immature markers such as Nestin and O4. A fraction of TAGs displayed sphere formation in stem cell
medium. Moreover, TAGs promoted brain tumour growth in vivo when co-implanted with glioma cells, compared to
implanting only glioma cells, or glioma cells and unconditioned glial cells from mice without tumours. Genome-wide
microarray analysis of TAGs showed an expression profile distinct from glial cells from healthy mice brains. Notably, TAGs
upregulated genes associated with immature cell types and self-renewal, including Pou3f2 and Sox2. In addition, TAGs
from highly angiogenic tumours showed upregulation of angiogenic factors, including Vegf and Angiopoietin 2.
Immunohistochemistry of three GBMs, two patient biopsies and one GBM xenograft, confirmed that the expression
of these genes was mainly confined to TAGs in the tumour bed. Furthermore, their expression profiles displayed a
significant overlap with gene clusters defining prognostic subclasses of human GBMs.
Conclusions: Our data demonstrate that glial host cells in brain tumours are functionally distinct from glial cells of
healthy mice brains. Furthermore, TAGs display a gene expression profile with enrichment for genes related to stem
cells, immature cell types and developmental processes. Future studies are needed to delineate the biological
mechanisms regulating the brain tumour-host interplay.
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Background
Glioblastomas (GBMs) are aggressive brain tumours,
characterised by angiogenesis and infiltrative growth [1].
They have a poor prognosis with virtually no long time
survivors, and new therapies are urgently needed. Al-
though glioma stem cells have been implicated in brain
tumourigenesis [2, 3], conflicting data suggest that addi-
tional mechanisms are involved [4, 5].
In the non-pathological state, the roles of glial cells in
the CNS overlap with functions of fibroblasts in other
organs, such as secretion of ECM components, provision
of structural support and homeostasis. Astrocytes can
adapt a spectrum of altered phenotypes [6] in health and
disease, in response to changing external cues. They may
regulate normal brain function by modulating transmis-
sion in glial and neuronal cell signalling networks [6].
Activation of astrocytes during trauma and inflammation
is characterised by proliferation, increased expression of
GFAP and release of cytokines and neurotrophic factors
[7]. Numerous studies show that fibroblasts in the
tumour microenvironment undergo activation to pro-
mote cancer growth [8–10]. This activated state is char-
acterised by cell proliferation, release of growth factors
and matrix metalloproteinases [11]. However, fewer
studies have so far addressed whether glial cells and
fibroblasts have similar roles in tumour progression.
We previously reported that astrocytes can modulate
the chemosensitivity of glioma cells to clinically relevant
drugs using a tumour-stroma co-culture model with gli-
oma cell-specific luminescence [12]. Recently, Sin et al.
[13] reported that astrocytes promoted invasion of the
GL261 glioma cell line in mice. Moreover, other glial cell
types such as oligodendrocyte progenitor cells have been
shown to promote neovascularisation in gliomas [14].
Thus, several studies suggest that heterotypic signalling
circuits involving glial host cells and glioma cells are in-
tegral parts of tumour progression. Previously, tumour-
associated astrocytes were studied in heterozygously
deleted Ink4a/Arf mice with PDGF-induced murine gli-
omas. Notably, these transgenic tumour-associated as-
trocytes displayed a gene expression profile distinct from
normal astrocytes, suggesting a role in antigen presenta-
tion [15]. However, these astrocytes carried a tumour
suppressor deletion that may limit the relevance of these
findings to the microenvironment of human glioma cells.
Thus, little data are available regarding how glial cells in
the tumour microenvironment are reprogrammed during
brain tumour progression and how this impacts on overall
disease course.
Investigating the role of tumour-associated glial cells
(TAGs) in malignant brain tumours is challenging since
no markers reliably distinguish reactive glial cells from
neoplastic glioma cells [16]. Additionally, glial cells are
phenotypically diverse [17] and cannot be identified by
any unifying marker. Previously, we established brain tu-
mours in nude rats with non-angiogenic and vascular,
mature GBM phenotypes using human GBM biopsies
[18, 19]. The non-angiogenic phenotype displays infiltra-
tive growth and atypia similar to GBMs, but with little
or no angiogenesis. The vascular, mature phenotype also
displays angiogenesis. In order to investigate the roles of
TAGs, we established these tumours in GFP-NOD/scid
mice [20], resulting in GFP+ host cells from two different
tumour phenotypes and GFP− tumour cells. TAGs were
obtained by FACS isolation of GFP+ cells, with simultan-
eous removal of cells expressing vascular or immune cell
surface markers CD31 and CD11b, respectively. Since
the onset of angiogenesis is considered a key event in
gliomas, coinciding with worsening of the prognosis
[21], we isolated TAGs from both the non-angiogenic
and the mature vascular GBM tumour phenotypes. We
then investigated their functional properties, and con-
ducted gene expression profiling of these TAGs that was
subsequently validated in human GBMs.
Methods
Cell culture
Biopsies were obtained with written consents of the pa-
tients from the Department of Neurosurgery, Haukeland
University Hospital, Bergen, Norway. Collection of
tumour biopsies was approved by the Regional Ethical
Committee (REK Vest). Biopsy spheroids were prepared
as previously described, and the resulting spheroids
have previously been shown to contain both glioma
cells as well as stromal elements from the brain [22]. In
brief, tissue samples were minced into 0.5 mm3 frag-
ments and placed into agar-coated tissue culture flasks
with complete DMEM; DMEM culture medium (Sigma-
Aldrich, St. Louis, MO, USA) containing 10% fetal bovine
serum (FBS) supplemented with NEAA, 100 U/ml Pen/
Strep and 400 μML-glutamine, all from Cambrex
(Cambrex, East Rutherford, NJ, US). Biopsy spheroids
were maintained in a standard tissue culture incubator
with 5% CO2 in air and 100% relative humidity at 37 °C
and the medium was changed once a week.
Animal experiments
Tumour xenografts were established as previously de-
scribed [18], In short, human GBM biopsy spheroids of
250 μm in diameter were selected after 1–2 weeks in
culture, using a microscope (Olympus CKX31, Olympus
Microscopy, Essex, UK) with a reticular eye piece. 10 bi-
opsy spheroids were implanted in each GFP-NOD/scid
mouse 1.5 mm to the right of the midline, 1 mm poster-
ior to the bregma suture and 2 mm below the cortical
surface. In experiments not involving FACS sorting, we
used NOD/scid mice (GFP negative). Marcain was
injected in the scalp and the mice were operated under
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isoflurane gas anaesthesia, immobilised in a stereotactic
frame (Model 900, David Kopf Instruments, Tujunga
USA). In the co-implantation experiments, we implanted
cell suspensions in PBS following the same operative
procedure. The cell suspensions contained 50,000
tumour cells, mixtures of 50,000 tumour and 50,000
TAGs or normal glial cells, and controls containing
50,000 TAGs only. In total we used 58 mice for estab-
lishing the tumour phenotypes in vivo, and the co-
implantation experiments. The mice used for isolation of
TAGs and normal glial cells were age-matched, fully
adult mice from both genders, 3–4 months old. The Na-
tional Animal Research Authority in Norway approved
the experiments, and the animals were kept in an isola-
tion facility at 25 °C (55% relative humidity) in a specific
pathogen free environment. They were fed a standard
pellet diet and provided water ad libitum.
MR imaging
MR images were acquired using a 7 T small-animal MR
scanner (Pharmascan, Bruker Biospin, Billerica, MA,
USA) as previously described [23]. In short, animals were
anesthetised using 1–2% isoflurane mixed with equal parts
N2 and O2 supplied via a mask. Animals were placed in a
prone position in a cradle containing a heating pad at
37 °C. Respiration was monitored throughout the ex-
periment (SA Instruments Inc., NY, USA).
MRI protocols were as follows: MR sequences in-
cluded T2-wegithed RARE sequence with TR/TE of
4200/35.2 ms, and T1-weighted RARE sequence before
and after subcutaneous injection of contrast agent,
0.1 ml of 0.5 mmol/ml Omniscan (Nycomed Amersham,
Oslo, Norway), with TR/TE 1000/9.0 ms. T1 and T2
weighted sequences had FOV of 2.0 × 2.0 cm and a
matrix size of 256 × 256. 12 slices, each 1 mm thick
were collected in all sequences.
Tumour dissociation
To flush out blood cells the mice were perfused with
saline buffer with heparin, before the brains were disso-
ciated. GBM xenografts and healthy brains from GFP-
NOD/scid mice were minced with scalpels, followed by
dissociation with 1 mg/ml collagenase/dispase (Roche,
Rotkreuz, Switzerland) and 0.125% DNase I (Sigma-
Aldrich) dissolved in complete DMEM for 60–90 min
at 37 °C. The dissociated tissue was washed with ice
cold HBSS and filtrated twice through a 70 μm cell
strainer (Millipore, Billerica, MA, USA). The cell sus-
pension was centrifuged on 300 g at 4 °C for 10 min.
Pellets were resuspended in PBS with 2% FBS.
FACS sorting
After dissociating the GBM xenografts, cells were stained
with anti-mouse CD31- APC and CD11b- APC antibodies
(1:100, eBioscience, San Diego, CA, USA) on ice in the
dark for 15 min, followed by washing twice with ice cold
FACS buffer (PBS with 1% FBS). Cells were filtered
through a 40 μm cell strainer (Millipore) to obtain a single
cell suspension. GFP-negative and -positive cells were ana-
lysed and separated using a cell sorter (FACS Aria SORP,
BD Biosciences, Erembodegem, Belgium). Separation was
based on gating for single cells (FSC-W/FSC-A), viability
by Sytox blue (LifeTechnologies, Carlsbad, CA, USA) ex-
clusion and GFP fluorescence. From the GBM xenografts,
endothelial cells and immune cells recognised by APC-
conjugated anti-CD31 and anti-CD11b were gated out.
We performed control fluorescence microscopy of the
cells collected from the sorting procedure for confirming
purity. In order to obtain normal glial cells as controls for
cell-cycle, FCM analysis of marker expression, sphere
formation and co-implantation studies we used the same
dissociation protocol for healthy mouse brains followed by
FACS isolation with exclusion of CD11b+ and CD31+
cells. Due to the high lipid content of normal mouse
brains, FACS sorting with exclusion of CD11b and CD31
from these samples was omitted as we were unable to ob-
tain sufficient amounts of RNA when FACS sorting. Thus,
we instead validated the gene expression analysis data ex-
tensively performing IHC of both mouse brains, which
confirmed the upregulation of markers as suggested by
the gene expression analysis (below).
Spheroid formation assay
Stromal cells isolated from GBM xenograft tumours and
from healthy mice brains were separately resuspended in
Neurobasal stem cell medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 1xB-27 (without Vitamin A),
1xGlutaMax I (Invitrogen), 20 ng/ml EGF (Sigma-Aldrich),
20 ng/ml FGF2 (R&D Systems, Minneapolis, MN) and
100 U/ml Pen/Strep (Cambrex). 1500 cells were seeded
in each well of a 6-well plate for each cell type. The cell
cultures were inspected daily, and sphere formation
(minimum 50 cells in a spheroid) was assessed after
9 days, by manual counting under an inverted micro-
scope (Olympus CKX31). Bright field images were ob-
tained with Nikon TE2000-E (Nikon Instruments Inc.,
Melville, NY, USA) using the NIS Elements Software
(Nikon Instruments Inc.).
RNA isolation
Total RNA was extracted using RNEasy Mini Kit (Qiagen,
Hilden, Germany). Briefly, the sorted cells were collected
by centrifugation and dissolved in RLT lysis buffer. The
remaining procedure was performed according to the
manufacturer’s instructions including treatment with
DNase I (Qiagen).
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Gene expression analysis
The global mRNA expression of each sample was mea-
sured using the Agilent Whole Mouse Genome 4×44K
Oligo Microarray with Sure Print Technology (Agilent,
Palo Alto, USA). 1 μg of DNase-treated total RNA was
converted into cDNA and Cy3-labeled cRNA using the
Low RNA Input Linear Amplification Kit PLUS, One-
Color kit (Agilent, Santa Clara, CA, USA). Microarrays
were scanned with an Agilent scanner G2505B bundle
and images were analysed using Agilent Feature Extrac-
tion Software v.9.1. After background correction and
normalisation, the resulting raw data files were imported
into the J-Express analysis suite [24] for preprocessing
and gene expression analysis. The gMeanSignal was used
as signal for each probe. Control probes were filtered
out and duplicate probes were combined by taking the
median signal of the probes. Signal intensities were
quantile normalised [25] to achieve an inter-array nor-
malised gene expression data matrix. Finally, the data
was log2 transformed and multiple probes for the same
Gene Symbol (Agilent annotation file 014868) were
combined using the MaxProbe statistics [26].
Immunocytochemistry and BrdU pulsing
Cells were fixed with 4% paraformaldehyde for 10 min,
and permeabilized for 4 min with 0.5% Triton X-100 in
PBS. Blocking was done using 0.5% BSA in PBS for
15 min. All steps were performed in room temperature.
Mice were pulsed intraperitoneally with BrdU (150 mg/kg)
45 min prior to harvesting and dissociating the brains.
Cells were incubated with mouse anti-BrdU (Abcam,
Cambridge, MA, USA) at 1:100, containing 3 μl (1U/μl)
DNase I (Qiagen) for 45 min at 37 °C. Following incuba-
tion, cells were washed in PBS and incubated with
secondary antibody (diluted 1:100 in blocking buffer)
for 45 min at 37 °C. The secondary antibody was
TXRD-conjugated goat anti-mouse (Southern Biotech,
Birmingham, AL, USA). After washing with PBS cells
were mounted with Vectashield mounting medium con-
taining DAPI (Vector Laboratories, Burlingame, CA, USA).
Fluorescent images were obtained with a Zeiss LSM 510
Meta confocal microscope (Carl Zeiss MicroImaging, Jena,
Germany), using a 63× oil immersion objective.
Immunohistochemistry
Mouse brains were embedded in Tissue-Tek O.C.T.
(Sakura Finetek, Alphen aan den Rijn, The Netherlands)
and snap frozen in isopentane (Sigma-Aldrich) cooled on
dry ice. Snap-frozen tissue was sectioned at 6 μm thick-
ness on a cryostat (Leica CM3050S, Leica Microsystems,
Wetzlar, Germany). Subsequent washes were done with
TBS-Tween20 (Sigma-Aldrich) wash buffer, 3×3 min, all
steps were performed at room temperature. The primary
antibodies used were: anti-ANGPT2 (1:100, Abcam),
anti-Msi1 (1:500, Abcam), anti-NG2 (1:100, Abcam),
anti-Sox2 (1:100, Abcam), anti-VEGF (1:20, Abcam),
anti-Vimentin (1:100, Abcam), anti-PDGFRα (1:100,
Cell Signaling Technology, Beverly, MA, USA), anti-
GFAP (1:500, Dako, Glostrup, Denmark), anti-Tubulin
β3 (1:100, Millipore), anti-HuNu (1:100, Millipore),
anti-FGF2 (1:100, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-IDH1 (Dianova, Hamburg, Germany)
and anti-POU3F2 (SC-2895, Santa Cruz). The secondary
antibodies used were: FITC-conjugated goat anti-rabbit
(1:200, Southern Biotech), FITC-conjugated goat anti-
mouse (1:200, Southern Biotech), TXRD-conjugated
goat anti-mouse (1:100, Southern Biotech).
Flow cytometry
TAGs and normal glial cells acutely isolated by FACS
were fixed in 4% PFA (Sigma-Aldrich) for 10 min, pel-
leted and permeabilized with 0.5% Triton X-100 (Sigma-
Aldrich) for 4 min. Samples were pelleted again and
blocked in 0.5% BSA (Sigma-Aldrich) for 15 min before
immunostaining. Antibodies were diluted to 1:100; anti-
GFAP (Dako), anti-Nestin (Abcam), anti-beta-tubulin III
(Abcam), anti-MBP (Millipore) and 1:10; anti-O4 (RnD
Systems) in 100 μl blocking buffer, and samples were
incubated in 100 μl staining reaction for one hour at
room temperature. Samples were washed in 3 ml block-
ing buffer, stained with Alexa Fluor 647-conjugated
secondary anti-mouse and anti-rabbit antibodies (both
from LifeTechnologies) in 100 μl for 45 min at room
temperature and washed in 3 ml blocking buffer.
Samples were resuspended in 100 μl 1xPBS before ana-
lysis, and cells stained with secondary antibodies alone
or IgM isotype control (for O4, BD Biosciences) were
used to set the gates. For cell cycle analysis, acutely iso-
lated TAGs and glial cells from normal mice brains
were fixed in 100% ice cold ethanol for 20 min, washed
in 1xPBS and incubated for 30 min in RNase (1 mg/ml,
Sigma-Aldrich) and propidium iodide (50 mg/ml,
Sigma-Aldrich). All staining was acquired on AccuriC6
(BD Biosciences) and FlowJo (FlowJo, LCC, Oregon, USA)
was used for analysis.
Statistics
Sphere formation was analysed using Student’s t-test
with a 2-tailed distribution analysis. Survival data were
analysed using the log-rank test. A p-value < 0.05 was
considered significant. Differentially expressed genes
were identified between pairs of sample groups, utilising
unpaired SAM [27] analysis implemented in J-Express
[24], with 1000 permutations, and considering the list of
genes with q < 0.05 as significantly differentially expressed.
Gene Ontology overrepresentation analysis was per-
formed in J-Express software using a Fisher exact test to
identify GO terms overrepresented among differentially
Leiss et al. BMC Cancer  (2017) 17:108 Page 4 of 13
expressed genes compared to the full data set. Func-
tional term analysis was performed using the DAVID
bioinformatics resource [28], with the Agilent Probe
IDs as the query. Gene Ontology (GO) terms were con-
sidered enriched if their Benjamini-Hoschberg-adjusted
p-value was less than 0.05 [29]. The analysis of overlap
with the human profile genes was done using a custom
R-script in the gplots package (http://cran.r-project.org/
web/packages/gplots/). A bootstrapping-based analysis
with resampling, corresponding to the number of genes
in each of the groups, was performed to estimate expected
random overlap (mean/sd). These values were subsequently
used to determine the probability (significance) of the ob-
served overlap. Human orthologues were identified using
mammalian orthology tables available through the mouse
genome informatics database at Jackson Laboratories
(http://www.informatics.jax.org/orthology.shtml).
Results
FACS isolation of GFP+CD11b−CD31− cells from gliomas in
GFP-NOD/scid mice provides a population highly purified
for host cells expressing glial markers
The experimental flow-chart is shown in Fig. 1a. We used
GFP-NOD/scid mice as a host to establish non-angiogenic
Fig. 1 Isolation of tumour-associated glial cells. a GBM spheroids established from patient biopsies are implanted in GFP-NOD/scid mice. The resulting
tumours are dissociated and GFP+ stromal cells are FACS- sorted with removal of CD31+ and CD11b + cells. b Flow cytometry histogram displays a
bimodal curve, reflecting a non-fluorescent and a fluorescent cell population (Upper panel, Y-axis; cell count, X-axis; GFP fluorescence). Control fluorescence
microscopy of cells sorted by GFP expression (middle panels) and after staining for human nuclear factor, a pan-human specific marker (HuNu, lower panels).
c ICC for GFAP, Nestin, β-tubulin III and BrdU as indicated. Scale bar: 50 μm, insert: 20 μm. d Representative histograms (left panels) from cell cycle analysis
of acutely isolated TAGs (n= 3, black) and control cells from normal mouse brain. (n= 3, white). Middle panel shows the percentage differences in S and
G2/M-phase between TAGs and control, while numbers for all cell cycle phases are outlined in the table (right)
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and vascular GBM xenografts from patient GBM biopsies
[18, 19] (Additional file 1: Figure S1a, b). These tumours
were dissociated and flow cytometry histograms showed
bi-modal curves, reflecting the presence of fluorescent host
cells and non-fluorescent tumour cells (Fig. 1b, top panel).
FACS sorting by GFP expression was conducted, with re-
moval of CD31+ and CD11b+ cells from the host cells
(Additional file 1: Figure S1c–e), providing GFP+CD31
−CD11b− cells. In total, we performed FACS of 14 xeno-
graft tumours, including 6 non-angiogenic and 8 mature
GBM phenotypes (Additional file 1: Figure S1c–e). The
average fraction of GFP+CD11b−CD31− host cells was
19.1% (12–26.5%, Additional file 1: Figure S1e), being high-
est in the non-angiogenic tumours. Immunocytochemistry
(ICC) and flow cytometry (FCM) analysis demonstrated
expression of Nestin, O4, GFAP and myelin basic protein
(MBP), whereas expression of the neuronal β-tubulin III
was low (Fig. 1c, and Additional file 1: Figure S1f). FCM
analysis of 3 GBM xenografts using antibodies against a
panel of glial markers confirmed that 96% of these cells
expressed GFAP and 90% expressed MBP consistent
with co-expression of several glial markers, whereas
Nestin and O4 were expressed at somewhat lower rates
(Additional file 1: Figure S1f). Thus, GFP+CD11b−CD31−
cells were defined as tumour-associated glial cells (TAGs).
Similarly, healthy mice brains (normal brains without tu-
mours) were dissociated and FACS sorted to obtain nor-
mal glial cells as controls and their expression of glial
markers were subsequently assessed by FCM (Additional
file 1: Figure S1f). Notably, a proportion of the TAGs were
BrdU-positive (insert, lower right panel Fig. 1c), suggesting
that these were actively cycling cells. Cell cycle distribu-
tion determined by FCM confirmed that a significantly
higher proportion of TAGs were in S or G2/M-phase,
compared to glial cells from normal brain (Fig. 1d).
Control fluorescence microscopy for GFP expression
(Fig. 1b, middle panels) as well as immunostaining
(Fig. 1b, lower panels) for a pan-human specific nuclear
antigen HuNu [30] confirmed high purity of the host
cell populations (>98%), with few tumour cells present.
The purity was also confirmed by implanting pure TAG
cell suspensions, which did not produce tumours (see
later section).
Tumour-associated glial cells form spheres in stem cell
medium and promote brain tumour growth in vivo
TAGs isolated from mouse brain GBM xenografts were
seeded in stem cell medium, and sphere formation was
compared with glial cells from healthy mouse brain
(Fig. 2a, left and middle panels, respectively). TAGs
formed spheres at a frequency of 1%, compared to 0.1%
for normal glial cells (p = 0.001, Fig. 2a, right panel). In
addition, some TAG spheres grew adherent (Fig. 2a, insert
left panel). We then assessed whether TAGs promoted
brain tumour growth in vivo. First, we isolated TAGs and
glioma cells from non-angiogenic xenografts, and re-
implanted glioma cells (n = 12, 6 in each group), either
with TAGs or as pure glioma cell suspensions (Fig. 2b, left
panel). In addition, 4 mice received only TAGs, and did
not develop tumours. Mice co-implanted with TAGs and
glioma cells had a shorter survival (98 days) than mice
implanted with glioma cells only (108 days), although the
difference was not significant (p = 0.062). One mouse re-
ceiving only TAGs died after almost 6 months, but histo-
logical examination showed no tumour in its brain or in
any of the other mice receiving TAGs only.
Since the onset of angiogenesis is a key event in brain
tumour progression, TAGs expressing angiogenic factors
may display additional tumour-promoting effects com-
pared to non-angiogenic TAGs. Thus, we also dissoci-
ated mature, vascular GBM xenografts and separated
glioma cells and TAGs from the suspensions. Glioma
cells were subsequently re-implanted in mice (n = 15) as
pure glioma cell suspensions (n = 5) or as mixtures of
glioma cells and either TAGs (n = 6) or unconditioned
glial cells from normal mouse brains (n = 4, Fig. 2b, right
panel). In addition, 4 mice received pure TAG popula-
tions. Mice co-implanted with glioma cells and TAGs
had a median survival of 87 days, significantly shorter
than for mice implanted with only glioma cells (median
survival 103 days, p = 0.001) and for mice implanted
with glioma and normal glial cells (median survival
101 days, p = 0.032). The slightly shorter survival for
mice receiving normal glial and glioma cells compared
to mice implanted with only glioma cells was not signifi-
cant (p = 0.17). Mice receiving only TAGs remained well
until the experiments were terminated after 6 months,
when histopathological examination showed no tumour
engraftment.
Tumour-associated glial cells have a distinct gene
expression profile and express markers associated with
primitive glia and CAFs
We next performed gene expression profiling, comparing
TAGs from non-angiogenic and mature GBM tumour
phenotypes to normal glial cells using the Agilent Whole
Mouse Genome 4 × 44 K Oligo Microarray. In total, we
analysed nine TAG samples, including four samples from
mature GBM and five samples from non-angiogenic
tumour phenotypes, and four samples from healthy mice
brains. Normalised fluorescence intensities showed little
variation between the samples (Fig. 3a, upper left panel).
Global hierarchical clustering, grouping individual
samples on the basis of similarity in gene expression
with other cases, showed groupwise segregation of glial
cells from normal brain and TAGs from the two tumour
phenotypes. Thus, all samples displayed a higher within-
group similarity, than with samples from other groups.
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We observed this pattern for all genes (Fig. 3a, lower left
panel), and when analysis was restricted to significantly
differentially expressed genes (q < 0.05) between TAGs
and normal glial cells. Global hierarchical clustering ana-
lysis over both genes and samples showed patterns of
over- and underexpressed genes in the TAG cell popula-
tion, relative to glial cells from normal brain (Fig. 3a,
upper and lower right panels). Among these, genes asso-
ciated with stem cells and precursor phenotypes were
upregulated in TAGs from both tumour phenotypes
compared to normal glial cells (Fig. 3b). Sox2, a tran-
scription factor associated with self-renewal [31], and
Musashi-1, involved in asymmetric cell division [32],
were both significantly upregulated in TAGs. In addition,
the CNS-specific foetal transcription factor Pou3f2, and
markers of neural stem cells and primitive glia, such as
Vimentin and Ng2, were significantly upregulated. These
latter markers have also previously been associated with
CAFs [33]. Pdgfrα, which reportedly is expressed in
pulmonary cancer-associated fibroblasts [34], was also
upregulated in TAGs. In total, 2864 genes were differen-
tially expressed between TAGs from all tumours and
normal glial cells (Fig. 3c, upper panel). Of these, 1105
genes were overexpressed in TAGs, while 1759 genes
were overexpressed in normal glial cells (Additional file
2: Table S1). Since TAGs were obtained from two differ-
ent tumour phenotypes, we also compared TAGs from
each phenotype separately with normal glial cells. 5407
genes were differentially expressed between normal glial
cells and TAGs from the non-angiogenic glioma pheno-
type (Fig. 3c, second panel from top), while 6415 genes
were differentially expressed between normal glial cells
and TAGs from the mature GBM phenotype (Fig. 3c,
second panel from bottom). Thus, more genes were dif-
ferentially expressed when normal glial cells were com-
pared to TAGs from the individual tumour phenotypes,
as opposed to comparing with both phenotypes collect-
ively. This may reflect that TAGs from the two tumour
phenotypes are different and carry unique signatures
that become masked when they are grouped. Therefore,
we also compared TAGs between the two phenotypes,
and found that 2975 genes were differentially expressed
between TAGs derived from non-angiogenic tumours
and mature GBM phenotypes (Fig. 3c, bottom panel).
We next investigated whether TAG expression profiles
had a resemblance to human expression profiles associ-
ated with prognostic subclasses of human gliomas [35]
(Fig. 4a). Interestingly, analyses revealed that the TAG
gene expression profiles were significantly enriched for
genes contained within the human proneural, mesenchy-
mal and proliferative glioma subgroups. Moreover, both
TAGs from mature and non-angiogenic phenotypes dis-
played larger overlap with the proneural than any of the
other human glioma subgroups.
Fig. 2 TAGs form spheres in vitro and promote brain tumour growth in vivo. a TAGs cultured in stem cell medium formed spheres (left panel),
whereas normal glial cell sphere formation was barely detectable (middle panel), and significantly lower (right panel). Scale bar: 100 μm b Survival
following implantation in mice with the cell suspensions indicated, 50 000 cells of each cell type. Mice were implanted with glioma cells and TAGs
from non-angiogenic (left panel) and mature GBM (right panel) phenotypes
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Finally, gene ontology analysis revealed that differ-
entially expressed genes were significantly enriched
for gene clusters related to biological processes
commonly altered in cancer, such as development,
differentiation, cell cycle progression, apoptosis, cell
motility and metabolism (Fig. 4b and Additional file
3: Table S2). Moreover, when comparing TAGs from
the mature GBM phenotypes to TAGs from non-
angiogenic gliomas, we observed a significant upreg-
ulation of Vegf, Angiopoietin 2 and Fgf2 (Fig. 4c).
Glial host cells in human GBMs express TAG related
markers
The glial host cell expression of markers for immature
cells, self-renewal and angiogenesis was confirmed with
immunostaining of human GBMs. In order to identify
host cells, we validated these markers in an EGFR amp-
lified human GBM, combined with FISH (assessing
EGFR chromosome gain and gene amplification) using
EGFR probes and CEP7 probes for the centromere re-
gion of chromosome 7, (Fig. 5a–i). We also performed
Fig. 3 TAGs display a distinct gene expression profile. a Boxplot showing the normalised fluorescence intensities of the labelled samples that
were analysed (upper left panel). Global hierarchical clustering of the samples (lower left panel) shows that samples from normal glial cells and
TAGs from non-angiogenic and mature GBM phenotypes group separately. Global hierarchical clustering analysis over both genes and samples
(right panels) show TAG gene clusters, both over- and underexpressed compared to normal glial cells. b Mean normalised expression profiles of
“stemness” genes are upregulated in TAGs. c The numbers of significantly overexpressed genes in various groups are shown in their respective
compartments in the non-overlapping areas (SAM analysis, q < 0.05). Genes that are not significantly differentially expressed are shown in the
overlapping areas
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doublestaining of an IDH1 mutated GBM with anti-
bodies both for the IDH1 mutation and the markers of
interest (Fig. 5j–r). Notably, both samples showed stro-
mal and tumour cell expressions of markers associated
with self-renewal and differentiation of CNS cell types
such as Musashi-1, SOX2, POU3F2, PDGFRA, GFAP
and Vimentin, as well as angiogenic factors including
FGF2, VEGF and Angiopoietin 2. However, GBMs dis-
play genetic heterogeneity. Snuderl et al. reported that
4–5% of GBMs expressed more than one receptor tyro-
sine kinase (RTK) [36]. Notably, the RTKs were not
present in the same tumour cell, providing a mosaic
amplification of RTKs within this subgroup of GBMs.
Although this was a relatively rare phenomenon, it
introduces the risk of mislabelling tumour cells as stro-
mal cells when using tumour cell mutations as the
defining criteria. We therefore conducted immuno-
fluorescence doublestaining of a GBM xenograft staining
against the pan-human specific nuclear antigen HuNu, to
obtain a definite distinction between glioma (violet nuclei)
and host cells (blue) in the tumour bed (Additional file 4:
Figure S2a–t). Moreover, staining GBM xenografts
allowed us to assess the spatial distribution of immuno-
positive cells throughout the tumour bed. Again, we
observed that several factors were expressed both by
tumour and host cells in the tumour core, including
Musashi-1 (Additional file 4: Figure S2a, f ) and SOX2
(Additional file 4: Figure S2b, g). Interestingly, host cell
expressions of several markers were strongly upregu-
lated towards the tumour bulk, but hardly visible out-
side the tumour region, including Vimentin and the
angiogenic factors Angiopoietin 2, VEGF and FGF2.
Similarly, PDGFRA expression, previously reported to
mediate recruitment of stromal cells [34], was not
detected in the parenchyma distant to the tumour, but
abundantly expressed in host cells infiltrating the
tumour (Additional file 4: Figure S2e, j).
Discussion
Our limited knowledge about brain tumour-host interac-
tions is mostly based on studies of tumour angiogenesis
involving the host vasculature and brain tumour im-
munity. Recently however, several reports have impli-
cated glial cells in this interplay [12, 14].
In this study, we isolated glial host cells from GBM xe-
nografts established in GFP-NOD/scid mice. Combined
with negative selection, by removing stromal endothelial
(CD31+) and white blood (CD11b+) cells, we obtained a
cell population expressing various glial cell markers but
only low levels of the neuronal β-tubulin III. Notably
96% of these cells expressed GFAP confirming their glial
phenotype. However, since glioma cells also express glial
Fig. 4 Gene ontology analysis of TAGs from non-angiogenic and mature GBM phenotypes. a Overlap between expression profiles of TAG populations
as indicated and human subclasses of GBM. TAGs from both phenotypes combined displayed a significant overlap with both the proneural
(p < 0.0001) and the proliferative (p < 0.0016) subclasses, but not the mesenchymal (p < 0.26) subgroup. Overlap between the individual TAG
phenotypes and all the human GBM subclasses were highly significant (p < 0.0001). b The bar chart shows percentages of the genes ascribed
to the biological processes indicated. All genes on the array chip were set as reference (green). The percentages of differentially expressed
genes ascribed to these processes are significantly higher (Fisher’s exact test, p < 0.05 after Bonferroni correction) both in TAGs from non-angiogenic
(yellow) and mature GBM phenotypes (purple). c Gene profiles of angiogenic factors significantly upregulated in TAGs from mature GBM phenotypes
compared to TAGs from non-angiogenic tumour and normal glia. ANGPT2: Angiopoietin 2, VEGF: Vascular endothelial growth factor, FGF2: Fibroblast
growth factor 2. PN: Proneural, MES: Mesenchymal, PROLIF: Proliferative
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markers, we confirmed their host origin using three dif-
ferent approaches: 1) Control fluorescence microscopy
for host cell GFP expression following every sorting, 2)
Immunofluorescent staining confirming the absence of
the pan-human specific marker Human Nuclear factor
(HuNu) in the stromal compartment, and 3) By
implanting GFP+ CD11b− CD31− cells in NOD/scid
mice, which were non-tumourigenic compared to the
implanted glioma cells.
Since immunofluorescence and FCM demonstrated
that GFP+ CD11b− CD31− cells isolated from the GBM
xenografts were highly enriched for various glial
markers, we named them tumour-associated glial cells
(TAGs). Had we instead isolated host cells from the
tumour bed by positive selection, guided by predefined
glial markers, cell populations expressing other glial
markers would have been missed. Thus, we believe the
observed expressions of several glial markers supports
our unbiased approach with isolation of all host cells,
followed by removal of cells expressing vascular and
endothelial cell markers. In the TAG populations, the
percentages of positive cells for the various markers
exceeded 100%, indicating that TAGs express several
glial markers simultaneously. However, the expression of
multiple glial markers is also consistent with the pres-
ence of different subpopulations of glial host cells.
Whether these subpopulations are also functionally dis-
tinct entities is not known. Future studies aimed at char-
acterisation of glial cells grouped by marker expression
may help clarify the role of different subpopulations.
Notably, a significant proportion of TAGs were in the S/
M-phase and TAGs also expressed Nestin. In addition,
TAGs displayed a sphere forming ability in stem cell
medium. The presence of a TAG subpopulation with
stem-like properties may reflect a reprogramming of ma-
ture glial cells in the tumour bed, recruitment of neural
precursor cells or bone marrow-derived cells, or a com-
bination of these. Thus, the origin of TAGs is not estab-
lished, and they may in principle have several different
sources.
Fig. 5 a-i EGFR (red) and CEP7 (green) FISH signals (left panels) and immunostaining of marker of interest (MOI, white, right panels). Images were
taken from the same area on the same sample. White and red arrowheads: Cells with diploid of EGFR-CEP7 signals (two of each) that are positive
for marker of interest, respectively. Counterstaining: Hoechst dye (blue). j-r Double staining for IDH1R132H-mutation (pseudored) and MOI (green).
White arrowheads: Cells that are negative for IDH1R132H-mutation but positive for MOI. Counterstaining: PI (pseudoblue). Scale bars: 25 μm
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Moreover, TAGs displayed a gene expression profile
distinct from glial cells from healthy brains, including an
upregulation of growth factors and growth factor recep-
tors consistent with an active role in the tumour-host
interplay. Interestingly, this included markers also
expressed by CAFs, suggesting that conditioning of glial
cells in the brain tumour microenvironment resembles
the activation of fibroblasts in other tumours [33, 34]. In
addition, their sphere forming ability in stem cell medium
was corroborated by an upregulation of immature markers
and foetal transcription factors. Importantly, TAGs and
glioma cells share a common environment and are ex-
posed to the same external cues. Thus, the niche that en-
dows glioma cells with stem-like properties may induce
similar changes in neighbouring TAGs.
Furthermore, TAGs from non-angiogenic and vascular
GBM xenografts had different expression profiles, sug-
gesting that TAGs co-evolve with the tumour cell com-
partment during tumour progression. Notably, TAGs
from the vascular GBM xenografts upregulated angio-
genic factors. This is consistent with their tumour-
promoting effects and may underlie the significantly
shorter survival we observed in our co-implantation ex-
periment with TAGs from vascular GBM xenografts.
The difference in median survival from 103 days when
implanting glioma cells only, to 87 days when co-
implanting glioma cells and TAGs, may seem marginal
but still provides proof-of-concept that brain tumour-
stroma interactions may impact on survival. It is there-
fore conceivable that the brain tumour-host interplay
can be targeted therapeutically.
Previously, our model has been shown to histopatho-
logically closely mimic patient tumours. Importantly, the
clinical validation of our gene expression data in human
GBMs, both with IDH1 mutations and with EGFR am-
plifications, further confirms their relevance to a patient
setting. A recent study however, showed that a fraction
of GBMs contains genetically distinct subclones, with
different tyrosine kinase mutations. Although this frac-
tion was reportedly small, representing 4.5% of a cohort
with 350 GBMs, it introduces the risk of misidentifying
tumour cells without the IDH mutation/EGFR amplifica-
tion as stromal cells [36]. We therefore conducted addi-
tional immunostaining of human GBM xenografts for
the markers of interest combined with a human-specific
antibody to obtain a definite identification of stromal
cells. Apart from confirming the previously performed
immunostainings on patient samples, it provided addi-
tional information by showing the spatial distribution of
host cells expressing TAG-related genes. Interestingly,
expression of upregulated genes in the TAG samples,
were mostly confined to the tumour bed, whereas glial
cells in the surrounding brain further away from the
tumour expressed these proteins at much lower levels.
We believe this further demonstrates that the TAG gene
expression profile reflects a conditioning to the tumour
microenvironment.
Previous genomic analyses of large GBM patient co-
horts have shown that EGFR and IDH1 mutated GBMs
fall in different prognostic GBM subclasses [37]. Since
these analyses are based on patient biopsies containing
both tumour and stromal cells, both cell compartments
may in principle contribute to a tumour’s genetic profile.
Previously, Katz et al. [15] investigated gene expressions
in GFAP expressing host cells from murine glioma of
heterozygously deleted Ink4a/Arf mice. Notably, their
microarray analysis also identified genes associated with
survival. Interestingly, we found that genes constituting
the TAG gene expression profile were significantly over-
represented in all human GBM subclasses. Although the
significance of these findings cannot be fully interpreted
and understood from this study alone, it suggests that
the reprogramming in glial cells of the tumour micro-
environment has a clinical relevance. Future studies may
clarify whether the gene expression of TAGs also provides
a prognostic signature: i.e. whether TAG profiles from in-
dividual patient samples show higher similarities to the
subgroup predicting the patient’s survival outcome.
Conclusions
The present data demonstrate that TAGs have a distinct
gene expression profile, involving stem cell and immature
markers. Moreover, TAGs contain a significant proportion
in S or G2/M-phase and display sphere formation in stem
cell medium further suggesting a stem-like phenotype.
Notably, TAGs from highly vascular xenografts also up-
regulate angiogenic factors and promote brain tumour
growth in vivo. In summary, these findings establish a role
for TAGSs as active participants in the brain tumour-host
interplay. However, the mechanisms behind activation of
glial cells in the tumour microenvironment are incom-
pletely understood.
Additional files
Additional file 1: Figure S1. MRI, H/E and flow cytometry of
non-angiogenic and mature GBM phenotypes. A) Upper panels: MRI
of non-angiogenic tumour. Contrast-enhanced T1 sequence (left)
shows no enhancement. T2 (right) shows a diffuse lesion (red arrowhead).
Lower panels: MRI of mature GBM phenotype. Contrasted T1 (left) shows
enhancement (white arrowhead) due to leaky tumour vessels and dark areas
of necrosis (red arrowhead). T2 (right) shows the tumour lesion. B) H/E
staining of nonangiogenic (upper) and mature GBM tumours (lower).
Non-angiogenic tumour with infiltrative growth (left) and cellular atypia
(right). The mature GBM phenotype displays shift of midline structures
(lower, left panel) and enlarged vessels, necrotic regions (white arrowhead)
and pseudopalisading cells (red arrowhead) surrounded by dilated vessels
(black arrowhead, lower right panel). Scale bars: left and right panels 100 μm.
C) Scatter plot of the cell suspension: gating for live cells (left), gating by APC
(CD11b and CD31) and GFP (right). D) Gating hierarchy and percentage
distribution of different cells types. E) Percentages of TAGs in the two tumour
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phenotypes as indicated. TS: tumour sample, −a, −i etc. refers to the individual
samples. F) Expression of various glial markers in GFP + CD11b-CD31- TAGs
and GFP + CD11b-CD31- cells from normal mouse brains. (JPG 1941 kb)
Additional file 2: Table S1. Gene list of all significantly over- and
underexpressed genes in pairwise comparisons, sorted after fold change
value. (XLS 921 kb)
Additional file 3: Table S2. GO term list of all significant GO terms in
pairwise comparisons, sorted after enrichment value. (XLS 127 kb)
Additional file 4: Figure S2. Expression of stem cell markers and
angiogenic factors in GBM xenografs. A-T) Immunostaining against the
markers (green) indicated in left panels. Sections are also stained for the
pan human specific marker HuNu (red). Nuclear counterstaining: DAPI
(blue). Left panels: Low magnification (×10 a, b and d, ×20 c, e and k-o)
showing the tumour bulk and periphery. The tumour cell nuclei appear
violet due to red HuNu and blue counterstaining. Right panels: High
magnification (×80 f-j and p-t, and inserts y160 f-j and p-t) of the
tumour bed. Scale bars: left panels 100 μm (a-e and k-o), right panels
25 μm (f-j and p-t) and inserts 5 μm (f-j and p-t). (JPG 3534 kb)
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